Liminatus Pharma, Inc. Class A Common Stock (LIMN) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Liminatus Pharma Inc (LIMN) 3-Minute Overview > **💡 One-Sentence Summary** > > Liminatus Pharma is a tiny, early‑stage biotech on NASDAQ that’s still pre‑profit, heavily loss‑making, and currently trading like a high‑risk lottery ticket rather than a stable business. > **📍 Basic Profile** > > Market Cap **$49.8 million** · Biotechnology · NASDAQ · Price **$1.84** --- > **⚡ 3 Things You Should Know** > > 1. ⚠️ Pre‑revenue, deep in the red: Negative ROA of about **‑66%** and no PE ratio basically tell you this is still R&D mode—any investment here is a bet on future clinical success, not current business performance. > > 2. 🧯 Liquidity stress: A **current ratio ~0.42** and **quick ratio ~0.21** are very low; in simple terms, near‑term cash/working capital looks tight, so capital raises (dilution or debt) are highly likely if they want to keep the lights on. > > 3. 🎢 Massive 52‑week swing: The stock went from **$33.66 high to a $0.54 low**, now at **$1.84**—that sort of collapse usually means sentiment flipped hard (failed expectations, financing overhang, or dilution), so this is more of a trading/speculation name than a fundamentals story right now. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------------|-----------|---------| > | Profitability | Weak👎 | Strongly negative ROA (~‑66%), no earnings, no PE | > | Growth Rate | [Data unavailable] | No revenue/earnings growth data provided | > | Financial Health| Tight🧡 | Current ratio 0.42, quick ratio 0.21, negative interest coverage | > | Valuation | [Unclear] | No PE; price collapsed vs 52‑week high, but fundamentals don’t justify a “cheap” label yet | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Liminatus develops biotech/pharma products (likely still in clinical or pre‑clinical stages) and will eventually rely on drug approvals or partnerships for revenue—but it doesn’t have a mature commercial business yet. **Revenue Breakdown:** Data not available; given the metrics (no PE, deep losses), it’s effectively a **pre‑revenue R&D biotech**, so you’re betting on pipeline success, not current sales. | Business | Share | Trend | Comment | |----------|-------|-------|---------| | R&D / pipeline | [Data unavailable] | [Data unavailable] | Core value is in future potential drugs; nothing commercial yet | | Commercial products | ~0% | → | No sign of a mature, cash‑generating product line | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |------------|-----------|--------------|----------------| | Gross Margin | [Data unavailable] | [Data unavailable] | Likely irrelevant at this stage (no or minimal product sales) | | Net Margin | [Data unavailable] | Below Average | Persistent losses typical of early biotech | | ROA | **‑65.56%** | Very weak | Company is burning capital aggressively with no current return | In other words, this is a **cash‑burning science project**, which is normal for early biotech, but it means fundamentals won’t “screen well” by any traditional metric. --- ### 📈 How's the Growth? **Growth Assessment:** [Unknown / likely no meaningful revenue growth data] | Metric | Latest | vs Last Year | Trend | |-----------------|--------------|--------------|-------| | Revenue Growth | [Unavailable] | [Unavailable] | [Unavailable] | | Profit Growth | [Unavailable] | [Unavailable] | [Unavailable] | **Growth Quality:** Here, “growth” really means **pipeline progress** (trial phases, approvals, partnerships), but we don’t have those details in your dataset. Without that, you can’t judge whether the story is improving or stalling—only that the market *used to price in* a much bigger story (at $30+) and now does not. --- ### 💰 Financial Health Check **One Sentence:** Think of Liminatus as someone with no stable income, a big research hobby burning cash, a weak buffer in their bank account, and interest costs already exceeding what they can comfortably handle. | Metric | Value | Safe Zone | Assessment | |--------------------|---------|-------------|------------| | Debt Ratio | [Unavailable] | <60% safe | [Unknown] | | Current Ratio | **0.42** | >1.5 healthy | 🚨Dangerous – struggles to cover short‑term obligations | | Quick Ratio | **0.21** | >1.0 better | 🚨Dangerous – very thin liquid cushion | | Interest Coverage | **‑15.4** | >3 comfortable | 🚨Dangerous – operating loss doesn’t cover interest at all | | Cash Flow | [Unavailable] | >0 | Likely negative, typical for early biotech | What this means in practice: **high risk of future dilution or unfavorable financing**. If you own shares, your stake may get watered down to keep the company alive. --- ### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: **$0.5399** - 52-Week High: **$33.66** - Current: **$1.84** Price position ≈ \[ \frac{1.84 - 0.5399}{33.66 - 0.5399} \approx 3.9\% \] So: **Very close to the low** of its 52‑week range. | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|-----------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(≈4%) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |-----------------|-----------------|---------------------|------------| | vs Own History | PE: N/A | 5-year avg: N/A | No earnings; only price history shows huge derating | | vs Peers | PE: N/A | Industry often N/A or high | For pre‑revenue biotech, valuation depends on pipeline, not earnings multiples | **What the Current Valuation is Betting On:** At a ~$50M market cap and near the 52‑week low, the market is basically saying: - “We **don’t** believe the earlier $30+ price story anymore,” and - “There’s still some option value that something in the pipeline might work, but odds or economics are questionable.” So you’re essentially paying for **optional upside on future trial success** with a non‑trivial risk of total or near‑total capital loss. --- ### 📰 Any Recent News? No structured news items were provided in your dataset. | Date | Event | Impact | |------|-------|--------| | [Data unavailable] | [No recent news in dataset] | Neutral – but for micro‑cap biotech, key info usually hides in SEC filings, trial updates, or financing announcements | If you care about this name, it’s important to manually check: • Latest 10‑K/10‑Q (cash runway, dilution, going‑concern warnings) • Clinical trial registry / company website for pipeline status • Recent offerings or reverse splits (common in names that fell from $30 to <$2) --- ## 📊 Layer 3: 3-Minute Complete Analysis ### I. Detailed Financial Data **Profitability Trends:** Your data only gives a single ROA figure; we don’t have multi‑year series. | Metric | This Year | Last Year | Year Before | 3-Year Trend | |------------|---------------|-----------|-------------|--------------| | Gross Margin | [N/A] | [N/A] | [N/A] | [N/A] | | Net Margin | [N/A] | [N/A] | [N/A] | [N/A] | | ROE | [N/A] | [N/A] | [N/A] | [N/A] | | ROA | **‑65.56%** | [N/A] | [N/A] | [Unknown] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------------|-----------|-----------|-------------|--------------| | Revenue Growth | [N/A] | [N/A] | [N/A] | [N/A] | | Profit Growth | [N/A] | [N/A] | [N/A] | [N/A] | | EPS Growth | [N/A] | [N/A] | [N/A] | [N/A] | Without time series, we can’t say whether things are getting “less bad” or worse—only that **the current state is clearly loss‑making and capital consumptive**. --- ### II. Earnings Track Record No earnings history data is provided. | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | [N/A] | [N/A] | [N/A] | [N/A] | **Earnings Trend Interpretation:** Since there are no consistent profits, the usual “beat vs miss” game isn’t meaningful. For this kind of stock, the real catalysts are: - Clinical trial results (success/failure, delays) - Regulatory milestones (INDs, Phase transitions, FDA feedback) - Financing events (dilution, PIPEs, warrants, reverse split) --- ### III. What the Market Thinks **Analyst Ratings:** No analyst recommendation data in your dataset—very common for **micro‑cap, early‑stage biotech**; many big brokerages simply ignore these names. | Rating | Count | Percentage | |------------------|-------|------------| | Strong Buy/Buy | 0 | 0% | | Hold | 0 | 0% | | Sell | 0 | 0% | **Target Price:** [Data unavailable] **vs Current Price:** [No official upside/downside range available] **Insider Activity:** [No data in your set] No insider data means we can’t tell if management has been buying the dip or cashing out—something worth checking via SEC Form 4s if you’re serious about this stock. --- ### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Financing / Dilution Risk:** Extremely low current and quick ratios plus negative interest coverage mean the company likely needs fresh capital. → This usually comes via **equity offerings**, which can heavily dilute existing shareholders and pressure the stock. 2. **Binary Clinical Risk:** As an early‑stage biotech, the entire valuation hangs on a small number of drug candidates. → Trial failures, delays, or safety issues could rapidly erase most of the remaining market cap. 3. **Listing & Liquidity Risk:** With a **very small ~$50M market cap** and a share price that already crashed from >$30 to under $2, there’s a non‑trivial risk of **reverse splits, potential NASDAQ compliance issues, and thin liquidity**. → This can create big gaps, high volatility, and difficulty exiting positions at fair prices. --- ## 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Liminatus Pharma is a tiny, early‑stage biotech that’s still in heavy R&D mode with no sustainable revenue and significant ongoing losses. > **Key strength:** The only real “strength” here is optional upside—if its pipeline delivers a positive surprise, the small market cap leaves room for large percentage moves. > **Key risk:** Financial stress and binary clinical outcomes mean high odds of dilution or capital loss; this behaves more like a speculative biotech option than a conventional investment. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】to dig into its science, IP, and whether any competitive edge could actually be durable. > • Want to check for hidden landmines? → Try【Muddy Mode】to scan filings for going‑concern warnings, financing terms, and any red flags. > • Is this a growth stock? Want to calculate if it’s worth the bet? → Try【Musk Mode】to frame upside/downside under different trial success/failure scenarios and dilution assumptions.